Janakiraman Subramanian, MD
Medical Oncology · Fairfax, VANPI 1366589343
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $352,984 of the $561,930 with a category attached, or 62.8%. 27 manufacturers reported payments, led by AstraZeneca at 33.3% of the total. 2025 is the largest year on record at $159,271, 4.2 times the $37,596 reported in 2019. Among medical oncology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 419 payments — averaging $1341.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$187K
- Merck$119K
- Jazz Pharmaceuticals Inc.$79K
- Johnson & Johnson$65K
- Boehringer Ingelheim$39K
- Daiichi Sankyo Inc.$19K
- plus $55K from 21 others
Across 291 payments — averaging $4727.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$432K
- Tesaro, Inc.$173K
- Novartis$132K
- GSK$132K
- Incyte Corporation$131K
- Genentech, Inc.$111K
- plus $265K from 9 others
What the payments were for
- Consulting fees$146,43826%
- Speaking & faculty fees$352,98463%
- Travel & lodging$55,77110%
- Food & beverage$6,7141%
- Education$230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 137 | $186,931 |
| Merck | 71 | $118,549 |
| Jazz Pharmaceuticals Inc. | 53 | $78,803 |
| Johnson & Johnson | 66 | $64,837 |
| Boehringer Ingelheim | 12 | $38,797 |
| Daiichi Sankyo Inc. | 19 | $19,387 |
| Sanofi | 14 | $9,536 |
| Amgen | 7 | $9,205 |
| Lilly USA, LLC | 10 | $8,318 |
| Pfizer | 2 | $4,405 |
| Daiichi Sankyo Europe GmbH | 3 | $3,990 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $3,038 |
| Novartis | 2 | $2,420 |
| Beigene, Ltd. | 1 | $1,950 |
| Novocure Inc. | 2 | $1,880 |
| AbbVie | 1 | $1,800 |
| Exelixis Inc. | 1 | $1,650 |
| Blueprint Medicines Corporation | 1 | $1,540 |
| Bayer | 1 | $1,140 |
| Genentech USA, Inc. | 1 | $1,070 |
| Janssen Scientific Affairs, LLC | 1 | $1,010 |
| G1 Therapeutics, Inc. | 1 | $750 |
| EMD Serono, Inc. | 1 | $500 |
| Coherus Oncology, Inc. | 2 | $260 |
| Janssen Global Services, LLC | 1 | $87 |
| Regeneron Healthcare Solutions, Inc. | 2 | $65 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KEYTRUDA$113,706
- TAGRISSO$82,591
- ZEPZELCA$78,351
- IMFINZI$64,840
- RYBREVANT$62,607
- GILOTRIF$37,637
- CARVYKTI$17,586
- DATROWAY$12,436
- Enhertu$11,251
- IMDELLTRA (AMG 757)$6,295
- ILARIS$2,350
- Cabometyx$1,650
- LIBTAYO$1,481
- OPTUNE LUA (NOVOTTF-200T)$1,380
- ALIMTA$1,272
- Vitrakvi$1,140
- TECENTRIQ$1,070
- COSELA$750
- Optune$500
- Tepmetko$500
How this compares
$561,930 in reported general payments places this provider in the 95th percentile of 95 medical oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 38 | $629,619 |
| RetevmoSelpercatinib | 14 | $317,959 |
| EliquisApixaban | 15 | $10,439 |
| Ondansetron Hcl | 29 | $2,423 |
| Dexamethasone | 40 | $548 |
| Prochlorperazine Maleate | 26 | $318 |
| Morphine Sulfate ErMorphine Sulfate | 11 | $187 |
| Olanzapine | 13 | $146 |
| Oxycodone Hcl | 16 | $122 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 11 | $108 |
| Levothyroxine Sodium | 15 | $100 |
| Gabapentin | 16 | $65 |
| Pantoprazole Sodium | 19 | $47 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $186,931 | $629,61938 claims |
| Lilly USA, LLCRetevmo, Olanzapine | $8,318 | $318,10527 claims |
| PfizerEliquis | $4,405 | $10,43915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 95 medical oncology providers in Virginia.
Other medical oncology in Fairfax
- Alexander SpiraFairfax$533K
- Roy BeveridgeFairfax$216K
- Kathleen HarndenFairfax$195K
- Nagla Abdel KarimFairfax$131K
- Lauren MauroFairfax$53K
- Donald TrumpFairfax$20K
- Timothy CannonFairfax$11K
- Arthur WinerFairfax$10K
- Danijela JelovacFairfax$7K
- Eun-Mi YuFairfax$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.